NICE backs BioCryst's Orladeyo for hereditary angioedema

BioCryst Pharma's Orladeyo has been recommended by NICE as a treatment for the rare disease hereditary angioedema (HAE) in England, Wales and Northern Ireland.

CSL accuses ex-exec, now at Pharming, of stealing trade secr...

HAE patients get new option as NICE backs Takeda's Takhzyro

Patients in England and Wales with hereditary angioedema (HAE) should soon have a new treatment option after NICE recommended Takeda’s Takhzyro (lanadelumab) should be funded by the NHS in

FDA rejects Pharming's Ruconest HAE label expansion

The FDA has rejected Pharming’s application to expand the licence of Ruconest, for a use as prophylaxis for patients with the serious rare disease hereditary angioedema (HAE).

Shire eyes blockbuster sales as FDA approves HAE therapy

The FDA has approved Shire’s first antibody-based preventive treatment for the rare disease hereditary angioedema, raising hopes for blockbuster-level sales as the company prepares for a ta

Shire plans filing for HAE drug after phase 3 success

Lanadelumab could revolutionise treatment of swelling disease.